Just reported
From Bristol Myers Squibb's results release of 29 października 2026; its quarterly report has since been filed.
Actual
13,07B USD
+6,9% y/y
+0,7% q/q
Guided
—
No guide given
Actual
1,05 USD
-2,8% y/y
-35% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Udziały w przychodach to szacunki za FY2025, a nie dane z raportu złożonego do regulatora.
Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.
Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.
Pełne sprawozdania finansowe →
Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.
Zbudowane z własnych raportów spółki Bristol Myers Squibb Co. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
The themes Bristol Myers Squibb is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
63,43 USD+1,7%zamknięcie 13 lis
Dane do 30 września 2026, z raportu 10-Q złożonego 29 października 2026
Bristol Myers Squibb discovers, makes and sells prescription medicines for cancer, blood disorders, immune conditions, heart disease and mental health conditions.
Prognoza spółki: przychody od 49B USD do 50B USD za Rok obrotowy 2026 — wzrost o 2,7% rok do roku
Grade C+
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 41 kwartałów historii ocen spółki Bristol Myers Squibb Co.. Pozostałe 39 sięgają do październik 2016.